

Special Issue

Surgical Treatment and Pathological Diagnosis of Liver Cancers: Current Status and Novel Perspectives

Message from the Guest Editor

Liver cancers are among the most common malignant tumors. They include primary liver lesions, mostly represented by hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), and secondary lesions, particularly metastatic colorectal cancer (mCCR). These three types of tumors vary greatly in their pathogenesis, behavior, and prognosis. Accordingly, their treatment rests on the evaluation of several elements, warranted by a multidisciplinary approach. Among others, surgical treatment is the most important approach for achieving long-term survival in these patients. This Special Issue aims to review the current status of surgery for HCC, CC and mCCR, to present research data prompting innovative surgical solutions, and to discuss how pathology can address the challenges raised by these advances

Guest Editor

Dr. Luca Di Tommaso

Department of Biomedical Sciences, Humanitas University, 20090 Milan, Italy

Deadline for manuscript submissions

closed (1 April 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/55745

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)